Truist Securities Reaffirms Buy Rating for PROCEPT BioRobotics, Adjusts Price Target to $50
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 15 2025
0mins
Source: Benzinga
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like PRCT with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on PRCT
Wall Street analysts forecast PRCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRCT is 51.75 USD with a low forecast of 38.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 30.020
Low
38.00
Averages
51.75
High
65.00
Current: 30.020
Low
38.00
Averages
51.75
High
65.00
About PRCT
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PRCT Options Analysis: Put Contract Offers 4.4% YieldBoost Potential
- Put Contract Yield: The $25.00 put contract for PRCT has a current bid of $1.10, and if an investor sells to open this contract, they commit to buying shares at $25.00, resulting in a cost basis of $23.90, which represents a 17% discount compared to the current price of $30.29, making it attractive for potential buyers.
- Expiration Risk Analysis: Current data suggests a 79% chance that the put contract will expire worthless, which would yield a 4.40% return on the cash commitment, or an annualized yield of 27.71%, referred to as YieldBoost, highlighting the contract's appeal.
- Call Contract Returns: The $32.50 call contract for PRCT has a current bid of $2.00, and if an investor buys shares at $30.29 and sells this contract, they could achieve a total return of 13.90% if the stock is called away at expiration, showcasing the potential profitability of this strategy.
- Volatility Comparison: The implied volatility for the put contract is 74%, while for the call contract it is 81%, compared to an actual trailing twelve-month volatility of 54%, indicating a high market expectation for future price fluctuations in PRCT stock, necessitating careful risk assessment by investors.
Continue Reading
ETFs on the Move This Monday: REMX, IHI
ETF Performance: The iShares U.S. Medical Devices ETF is underperforming, down approximately 1.7% in Monday afternoon trading.
Weakest Components: Notable declines among ETF components include Axogen, which fell by about 4.9%, and Procept Biorobotics, down by about 4.2%.
Market Context: The article provides insights into the performance of specific ETFs and their components, reflecting broader market trends.
Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
Continue Reading